Mizuho Securities Raises Price Target on Jazz Pharmaceuticals (JAZZ) Following FDA's Defitelio Approval
Tweet Send to a Friend
Mizuho Securities reiterated a Neutral rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and raised the price target to $137.00 (from $124.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
